Kate Haviland, Blueprint Medicines CEO

Roche and Blue­print agree to end col­lab­o­ra­tion for can­cer drug Gavre­to

Roche is re­turn­ing de­vel­op­ment and com­mer­cial­iza­tion rights for can­cer drug Gavre­to to Blue­print Med­i­cines.

The two com­pa­nies are dis­solv­ing their col­lab­o­ra­tion fol­low­ing a Roche de­ci­sion to opt out for “strate­gic rea­sons,” a Blue­print spokesper­son told End­points News in an email. The re­turn of the rights to Blue­print ex­cludes Gavre­to in Greater Chi­na where Roche al­ready has a li­cense agree­ment with CStone Phar­ma­ceu­ti­cals to com­mer­cial­ize the drug, ac­cord­ing to a news re­lease on Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA